Skip to main content
    P

    ProKidney Corp. (PROK)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.46
    -0.01 (-1.02%)

    Market Cap: $606.76M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    71%(12/17)
    Avg Surprise
    +14.42%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.14
    Range$-0.17 - $-0.12
    5 analysts
    EPS Revisions
    1
    0
    7d
    1
    2
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.15+9.1%
    60d ago$-0.14+1.1%
    30d ago$-0.14+1.1%
    7d ago$-0.14+1.1%
    Current$-0.14
    Revenue Consensus
    $124600
    Range$0 - $200000
    5 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.15
    Range$-0.24 - $-0.08
    5 analysts
    Revenue Consensus
    $133290
    Range$-373850 - $426150
    7 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.15---
    Sep 26EST
    		-$-0.14---
    Jun 26
    Reported Aug 10
    		$-0.15$-0.13-15.38%Miss-15.4%
    Mar 26
    Reported May 15
    		$-0.14$-0.14-1.82%Miss-7.7%
    Dec 25
    Reported Mar 18
    		$-0.14$-0.15+6.67%Beat+17.6%
    Sep 25
    Reported Nov 10
    		$-0.12$-0.14+14.29%Beat+14.3%
    Jun 25
    Reported Aug 12
    		$-0.13$-0.14+7.14%Beat+18.8%
    Mar 25
    Reported May 12
    		$-0.13$-0.16+18.75%Beat+18.8%
    Dec 24
    Reported Mar 17
    		$-0.17$-0.15-13.33%Miss-88.9%
    Sep 24
    Reported Nov 12
    		$-0.14$-0.22+36.36%Beat+22.2%
    Jun 24
    Reported Aug 9
    		$-0.16$-0.18+11.11%Beat-14.3%
    Mar 24
    Reported May 10
    		$-0.16$-0.18+11.11%Beat+0.0%
    Dec 23
    Reported Mar 21
    		$-0.09$-0.17+47.06%Beat+18.2%
    Sep 23
    Reported Nov 14
    		$-0.18$-0.14-28.57%Miss-38.5%
    Jun 23
    Reported Aug 10
    		$-0.14N/A+65.85%Beat-150.9%
    Mar 23
    Reported May 11
    		$-0.16$-0.12-33.33%Miss-33.3%
    Dec 22
    Reported Mar 28
    		$-0.11N/A+54.17%Beat-83.3%
    Sep 22
    Reported Nov 14
    		$-0.13N/A+58.06%Beat-1200.0%
    Jun 22
    Reported Aug 12
    		$-0.06$-0.06+7.00%Beat-458.0%
    Mar 22
    Reported May 16
    		$-0.12N/AN/ABeat-
    Dec 21
    Reported Mar 24
    		$-0.06N/AN/ABeat-
    Sep 21
    Reported Nov 15
    		$-0.01N/AN/ABeat-
    Jun 21
    Reported Aug 16
    		$-0.01N/AN/ABeat-
    Mar 21
    Reported Jun 9
    		$0.00$0.00N/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-2.65EV/EBITDAN/A
    Price/FCF-1.70xFCF Yield-58.85%
    Profitability
    Profit Margin0.00%Operating Margin-32249.00%
    ROE-59.00%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest Coverage-9327.16x
    Current Ratio8.36xQuick Ratio8.36x
    Trading Statistics
    Beta1.80Avg Volume1.67M
    52-Week High$3.4852-Week Low$1.30

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$1.60
    SMA 20$1.65
    SMA 50$1.68
    SMA 200$1.87
    EMA 10$1.59
    EMA 20$1.64
    EMA 50$1.68
    EMA 200$1.81

    MACD

    Line: -0.05Signal: -0.03Hist: -0.02

    ADX

    ADX: 15.5+DI: 17.9-DI: 28.9

    Aroon & PSAR

    Aroon Up24.0
    Aroon Down96.0
    PSAR$1.73

    Bollinger Bands

    Upper Band$1.87
    Lower Band$1.44
    %B Position2651%(Upper)
    Band Width0.05

    RSI (14-Day)

    Neutral
    37.8

    Momentum Oscillators

    Stoch %K15.8
    Stoch %D28.1
    Williams %R-87.1
    ROC (10d)-14.9%
    Momentum-0.26
    CCI (20d)-173.3
    MFI (14d)45.5

    Volatility Measures

    ATR (14d)$0.11(7.6%)
    StdDev (20d)0.11
    Hist Vol76.2%(High)

    Volume Flow

    VWAP$1.45
    OBV549.0M
    AD Line-137.9M
    CMF (20d)0.077

    Volume Metrics

    Avg Vol (20d)1.7M
    Vol Ratio0.4x(Low)
    VWMA (20d)$1.71

    Pivot Points

    R3$1.72
    R2$1.64
    R1$1.56
    Pivot Point$1.48
    S1$1.40
    S2$1.32
    S3$1.24

    Advanced Oscillators

    TSI-12.00
    Ultimate Osc50.9
    KST-62.38

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$150,000$226,000$225,000$217,000$221,000$230,000$76,000$0$0$0$4.49M$0
    Cost of Revenue$0$0$1.45M$0$0$0$-1,720,000$0$0$0$1.03M$0
    Gross Profit$150,000$226,000$225,000$217,000$221,000$230,000$76,000$0$0$0$3.46M$0
    Operating Expenses$48.52M$45.16M$45.60M$38.76M$39.93M$41.62M$51.65M$48.97M$43.06M$40.08M$24.21M$46.62M
    R&D$36.09M$33.84M$34.16M$26.82M$25.88M$27.26M$39.78M$31.25M$29.40M$27.23M$22.53M$32.20M
    SG&A$12.43M$11.32M$11.44M$11.94M$14.05M$14.36M$11.87M$17.72M$13.65M$12.84M$1.68M$14.42M
    Operating Income$-48,373,000$-44,933,000$-45,371,000$-38,539,000$-39,709,000$-41,388,000$-51,571,000$-48,973,000$-43,056,000$-40,076,000$-24,210,000$-46,617,000
    Interest Income$1.94M$2.33M$2.94M$3.26M$3.59M$4.03M$4.79M$5.58M$4.54M$4.84M$5.28M$5.54M
    Interest Expense$1,000$15,000$1,000$2,000$1,000$0$2,000$2,000$3,000$2,000$3,000$2,000
    Income Before Tax$-46,436,000$-42,621,000$-42,437,000$-35,283,000$-36,117,000$-37,361,000$-46,781,000$-43,395,000$-38,522,000$-35,235,000$-18,933,000$-41,078,000
    Income Tax Expense$0$0$-1,585,000$560,000$848,000$591,000$1.70M$-2,342,000$-56,000$98,000$2.79M$913,000
    Net Income$-46,436,000$-42,621,000$-40,852,000$-35,843,000$-36,965,000$-37,952,000$-48,483,000$-41,053,000$-38,466,000$-35,333,000$-21,724,000$-41,991,000
    EBITDA$-46,695,000$-43,275,000$-43,534,000$-36,866,000$-38,244,000$-39,788,000$-49,997,000$-47,487,000$-41,786,000$-38,974,000$-23,064,000$-45,612,000
    EBIT$-48,373,000$-44,933,000$-45,371,000$-38,539,000$-39,709,000$-41,388,000$-51,571,000$-48,973,000$-43,056,000$-40,076,000$-24,210,000$-46,617,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about PROK

    News

    ProKidney director Brian Pereira sells $1.07 million in shares

    ProKidney director Brian Pereira sold 757,164 shares of Class A Common Stock for approximately $1.07 million between August 18 and August 20, 2026. The sales were made at prices ranging from $1.3712 to $1.4407 per share...

    Investing.com•8/21/26•Somewhat-Bearish

    ProKidney Director Brian JG Pereira Completes Sale of All Class A Shares Over Three Days

    ProKidney Director Brian JG Pereira sold his entire holding of Class A Common Stock over three consecutive trading days, from August 18 to August 20, 2026. These transactions, both direct and indirect through a trust...

    Kalkine Media•8/21/26•Bearish

    ProKidney (PROK) director sells 757K shares over 3 days

    ProKidney Corp. (PROK) director Brian J. G. Pereira reported selling a total of 757,164 shares of Class A Common Stock between August 18–20...

    Stock Titan•8/20/26•Bearish

    Morgan Stanley (PROK) filings show ProKidney stake at 4.7% and below 5% level

    Morgan Stanley and its affiliate, Morgan Stanley Investment Management Inc., have reported their current beneficial ownership in ProKidney Corp. Class A common stock through a Schedule 13G/A amendment. Both entities now...

    Stock Titan•8/12/26•Neutral

    ProKidney Corp. (NASDAQ: PROK) warns on cash runway after $89M H1 loss

    ProKidney Corp. reported a net loss of $89.1 million for the first half of 2026 and flagged substantial doubt about its ability to continue as a going concern...

    Stock Titan•8/11/26•Bearish

    PROK Valuation and Fair Value

    P/E
    -2.6x
    P/FCF
    -1.7x
    P/B
    -0.3x
    See GNG's fair value

    PROK Profitability: Margins, ROIC and FCF

    Gross margin
    100.0%
    Operating margin
    -32249.0%
    Net margin
    0.0%
    ROE
    -59.0%
    FCF margin
    -19527.4%
    FCF yield
    -58.8%

    PROK Competitors

    CompanyTicker
    Zevra Therapeutics Inc.ZVRA
    Sophia Genetics SASOPH
    SurModics IncSRDX
    Phathom Pharmaceuticals IncPHAT
    Pacific Biosciences of CaliforniaPACB
    Olema Pharmaceuticals IncOLMA
    Performant Healthcare, IncPHLT
    Ironwood Pharmaceuticals IncIRWD

    Sector: Healthcare

    PROK Bull Case vs Bear Case

    Bear case

    • PROK's quarterly revenue changed -32.1% year over year.

    PROK Earnings: Beat Rate and Next Report

    Beat rate
    5 of 8 quarters (62.5%)
    Average surprise
    6.6%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.14
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    1 up, 2 down

    Frequently Asked Questions About PROK

    Does PROK pay dividends?

    ProKidney Corp. (PROK) does not currently pay a regular dividend.

    What is PROK's market cap?

    ProKidney Corp. (PROK) has a market capitalization of $606.76M with a current stock price of $1.46.

    Related stocks

    Sector: Healthcare

    All stocks starting with P

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In